NCT07298538Active, not recruiting
Long-Term Survival With Lenvatinib-Based Therapy in Unresectable Liver Cancer
Long-term Survival of Unresectable Hepatocellular Carcinoma Patients Receiving Lenvatinib-based Therapy: A Retrospective, Multicenter Propensity Score Matching Study
Source: ClinicalTrials.gov · Last updated 23 Dec 2025
Brief summary (registry, in English)
This study reviewed real-world outcomes of patients with unresectable hepatocellular carcinoma who received lenvatinib-based treatment. The study evaluated long-term survival, treatment response, and safety using data collected from six hospitals.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 800 (estimated)
- First submitted
- 25 Nov 2025
- Start date
- 1 Jan 2019
- Primary completion date
- Dec 2025
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07298538
What you commit to
- Study type: Observational
- Planned participants: 800
- From 1 Jan 2019 to the primary completion date, Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with other inadequately treated malignant tumors previously or currently.
- Prior liver transplantation/hepatectomy/ablation for liver cancer.
Other illness
- Patients with a pathological diagnosis of combined hepatocellular and intrahepatic cholangiocarcinoma (cHCC-ICC), cholangiocarcinoma, or other non-HCC malignant tumors.
Other
- Patients with no overall survival (OS) endpoint observed, and a follow-up period after treatment initiation of less than 6 months.
Who the study is looking for
- ≥ 18 years of age
- Patients with histologically or radiologically confirmed HCC who were newly diagnosed between January 2019 and December 2022 (meeting the diagnostic criteria of the American Association for the Study of Liver Diseases or the Chinese Guidelines for the Diagnosis and Treatment of Primary Liver Cancer).
- Patients with at least 1 measurable lesion in the liver per RECIST v.1.1.
- Initially unresectable HCC as determined by the investigator (including oncologically unresectable, surgically unresectable, or both).
- Child Pugh score ≤ 7
- ECOG-PS 0-1
- Patients who had not received any previous systemic therapy before receiving dual therapy (lenvatinib + immunotherapy/local therapy) or triple therapy (lenvatinib + immunotherapy + local therapy) as the first-line therapy. Combination therapy is defined as the initiation of immunotherapy or local therapy within 30 days (before or after) of the first dose of lenvatinib.
- Patients who had basic image data (CT/MRI/PET) and underwent at least one imaging evaluation during the systemic therapy (if the image data was obtained from other hospitals, the original data shall be provided for re-evaluation).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tianjin Medical University Cancer Institute and Hospital Coordinator of this site? Confirm its status | Tianjin | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.